Marc Peschanski is MD (1978), PhD (1980) and DSc (1985), and currently Scientific Director of the I-STEM Institute (Institute for Stem cells Therapy and Exploration of Monogenic diseases), based at the Evry Genopole (France). I-Stem is entirely dedicated to the exploration of stem cell therapeutic potentials in rare diseases of genetic origin, including cell therapy and pharmacology derived from stem cell modeling.
His team performed the first transplants of fetal neurons in France in 1991 in patients with Parkinson’s disease, and the world’s first in patients with Huntington’s chorea in 1996, as well as a gene therapy trial in patients with Huntington’s disease in 1998, with intra-cerebral transplantation of CNTF-producing cells. More recently, he has developed treatments using repurposed drugs for Steinert myotonia and Phelan-McDermid autistic syndrome, identified via the exploration of patients-derived pluripotent stem cells. He has recently started a first cell therapy clinical trial using embryonic stem cell-derived retinal pigmented epithelial cells for patients with retinitis pigmentosa.
Co-founder and first chairman of the European Network of NeuroTransplantation (NECTAR) in 1991, he has since coordinated several European research networks in gene and cell therapies.